Long-Term Results Following Transcatheter Aortic Valve Implantation

Pablo Codner 1 Abid Assali 1 Hanna Vaknin-Assa 1 Yaron Shapira 1 Gabriel Greenberg 1 Katia Orvin 1 Leor Perl 1 Soraya Taic 1 Marina Kupershmidt 1 Ram Sharoni 2 Tamir Bental 1 Alexander Sagie 1 Ran Kornowski 1
1Cardiology, Rabin Medical Center & Sackler Faculty of Medicine Tel Aviv University, Petah Tikwa, Petah Tikwa, Israel
2Cardiothoracic Surgery, Rabin Medical Center & Sackler Faculty of Medicine Tel Aviv University, Petah Tikwa, Petah Tikwa, Israel

Background Transcatheter aortic valve implantation is the contemporary treatment of choice for high/prohibitive surgical risk patients with severe symptomatic aortic stenosis.

Methods Outcomes of 329 (57% female) severe aortic stenosis patients, treated with TAVI and followed up to 3 years (mean 886 days), were analyzed and reported according to the Valve Academic Research Consortium 2 definitions. The primary end point was death from any cause.

Results This patient group was characterized by advanced age (mean 82±6.4), high mean logistic EuroScore = 19.1±12 and STS score = 8.1±5. The Medtronic-CoreValve®, the Edwards-Sapien®, the Corevalve Evolut R® and the Lotus Valve Systemtm  device, were utilized in 230 (70%), 94 (29%), 2 (0.6%) and 3 (0.9%) of patients; respectively. The trans-femoral, trans-axillar, trans-apical, trans-aortic and retroperitoneal route were used in 278, 17, 32, 1 and 1 of the cases; respectively. Procedural success was 96%. However, according to the VARC 2 definitions, device success was achieved in only 92.7% of cases since there was a need for a second valve implant in 11 (3.3%) patients. One month, 1 year, 2 and 3 years and 4 years survival rates were 99%, 95%, 94%, 88% and 78%; respectively. There were 3 (0.9%) patients who needed urgent cardiac surgery. Any vascular complications occurred in 71 (21.5%). Peri-procedural\in-hospital stroke was diagnosed in 14 (4.2%) patients. Permanent pacemaker was required in 53 (16.1%) patients: (49 cases in CoreValve and 4 in Sapien valves). Paravalvular leak (≥moderate) was noted in 32 (10%) patients. The median length of hospital stay was 5±4.3 days. After the procedure, mean valve gradients decreased from 53.6±14 to 7.2±7 (p<0.001). Symptomatic improvement was evident during follow up, having 98% of patients in NYHA-FC I or II. 

Conclusions Transcatheter aortic valve implantation is associated with excellent outcomes in elderly patients with severe symptomatic aortic stenosis. This report also demonstrates the long durability of the implanted devices.  

KM

 









Powered by Eventact EMS